Carasent Beheer

Beheer criteriumcontroles 0/4

De CEO Carasent's is Daniel Ohman, benoemd in Nov2022, heeft een ambtstermijn van 1.92 jaar. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde NOK 2.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 2 jaar.

Belangrijke informatie

Daniel Ohman

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.9yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

May 11

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Mar 18

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

Nov 22

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

May 06

Returns Are Gaining Momentum At Carasent (OB:CARA)

Apr 29

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Feb 13

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Nov 24

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

May 23

We Like These Underlying Trends At Carasent (OB:CARA)

Feb 28

What Type Of Shareholders Own The Most Number of Carasent ASA (OB:CARA) Shares?

Jan 24

CEO

Daniel Ohman (44 yo)

1.9yrs

Tenure

Mr. Daniel Ohman was the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager of VG...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Svein Bjornstad	Chief Financial Officer	3.2yrs	geen gegevens	0.49% NOK 6.4m
Daniel Ohman	Chief Executive Officer	1.9yrs	geen gegevens	0.22% NOK 2.9m
Johan Eltes	Chief Technical Officer	2yrs	geen gegevens	geen gegevens
Jon Schultz	Legal Counsel	no data	NOK 45.00k	geen gegevens
Stefan Jernberg	Chief Compliance Officer	less than a year	geen gegevens	geen gegevens
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 538.66k	geen gegevens
Cornelia Broqvist	Chief Marketing Officer	2.1yrs	geen gegevens	geen gegevens
Anna Larsson	People and Culture Manager	no data	geen gegevens	geen gegevens
Vilma Jonson	Head of Strategy	1.1yrs	geen gegevens	0.033% NOK 439.3k

2.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van CARA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tomas Meerits	Director	1.4yrs	geen gegevens	geen gegevens
Camilla Skoog	Independent Director	2.5yrs	geen gegevens	0.013% NOK 170.1k
Ulrika Sundling	Independent Director	2.5yrs	geen gegevens	0.028% NOK 364.0k
Petri Niemi	Independent Chairman of the Board	2yrs	geen gegevens	0.017% NOK 223.2k
Henric Carlsson	Independent Director	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CARA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Carasent Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Recent updates

High number of new and inexperienced directors

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA's (OB:CARA) 32% Jump Shows Its Popularity With Investors

New major risk - Share price stability

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Calculating The Fair Value Of Carasent ASA (OB:CARA)

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Is It Too Late To Consider Buying Carasent ASA (OB:CARA)?

New minor risk - Share price stability

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Price target decreased by 9.4% to kr29.00

Chief Executive Officer recently bought kr96k worth of stock

Carasent's (OB:CARA) Returns On Capital Are Heading Higher

Chief Executive Officer recently bought kr97k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.53 loss

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

Price target decreased by 12% to kr33.50

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Price target decreased by 8.6% to kr37.00

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to kr40.50

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Price target decreased to kr44.50

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to kr46.50

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to kr48.50

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Returns Are Gaining Momentum At Carasent (OB:CARA)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to kr54.00

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Price target increased to kr61.00

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)